DSpace Repository

Elotuzumab Plus Pomalidomide or Lenalidomide is Able to Achieve Durable >= Vgpr Responses Among Immunomodulatory/Proteasome Inhibitor Refractory Myeloma Patients: A Report on Multicenter Experience From Turkey

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)